Compare Medtronic PLC (MDT) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Atlassian Corporation PLC — how do they compare? Medtronic PLC trades at $82.68 (market cap $106.61B), while Atlassian Corporation PLC trades at $90.85 (market cap $23.67B). The key difference: Medtronic PLC is far larger — about 4.5× Atlassian Corporation PLC's market cap, and Medtronic PLC pays a 3.46% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| MDT | TEAM | |
|---|---|---|
Market Cap | $106.61B | $23.67B |
Sector | Health | Technology |
52-Week High | $105.35 | $203.00 |
52-Week Low | $73.75 | $57.15 |
Enterprise Value | $125.36B | $23.78B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
TEAM trades at $96.63, up 3.58% with bullish technical signals and strong analyst support. Revenue growth accelerated to $5.22B in 2025, though net margins remain negative at -4.93%. Recent AI-driven product launches and service collection surpassing $1B ARR highlight innovation momentum. The stock faces resistance near $97 with support at $92.
Outlook remains positive given consensus price target of $114.54 (18.5% upside) and 29 buy ratings. Risks include persistent unprofitability, competitive pressure from Microsoft/ServiceNow, and projected negative cash flow in 2026. Valuation appears reasonable with P/S of 3.96 versus sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
